| 乙型肝炎病毒携带者肾移植术后应用他克莫司和环孢霉素A的临床研究 |
| |
| 引用本文： | 刘小友,于立新,付绍杰,徐健,杜传福,邓文锋,王亦斌,叶桂荣,张彦选.乙型肝炎病毒携带者肾移植术后应用他克莫司和环孢霉素A的临床研究[J].南方医科大学学报,2007,27(7):1090-1092. |
| |
| 作者姓名： | 刘小友 于立新 付绍杰 徐健 杜传福 邓文锋 王亦斌 叶桂荣 张彦选 |
| |
| 作者单位： | 南方医科大学南方医院器官移植科,广东,广州,510515 |
| |
| 摘 要： | 目的 比较他克莫司和环孢霉素A在乙型肝炎病毒携带者肾移植术后的疗效和安全性.方法 符合入选标准的109例肾移植患者,随机分成他克莫司(FK506)治疗组(52例)和环孢霉素A(CsA)治疗组(57例),随访2年,比较两组的人肾存活率、急性排斥反应(AR)发生率、肝功能异常发生率和药物转换率等.结果 CsA和FK506组的2年人肾存活率分别为86.0%/73.7%和94.2%/90.3%(P＜0.05).AR发生率分别为10.5%和9.6%(P＞0.05).CsA组和FK506组的肝功能异常发生率分别为26.3%和15.4%(P＜0.05).CsA组有21.1%的患者接受静脉护肝药物治疗,而FK506组为9.6%(P＜0.05).CsA组有14.4%的患者转换为FK506,而FK506组没有病人转成CsA(P＜0.05).转换后,谷丙转氨酶/谷草氨酶在10～50 d内由(255.13±31.38/201.88±21.25)U/L)]降至(31.25±11.50/25.13±9.68)U/L](P＜0.01).结论 对乙型肝炎病毒携带者肾移植患者,FK506比CsA有更好的疗效和更高的安全性,可作为首选的基础免疫抑制剂.
|
| 关 键 词： | 乙型肝炎病毒携带者 肾移植 普乐可复 环孢霉素A |
| 文章编号： | 1673-4254（2007）07-1090-03 |
| 修稿时间： | 2006-10-15 |
Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients |
| |
| LIU Xiao-you,YU Li-xin,FU Shao-jie,XU Jian,DU Chuan-fu,DENG Wen-feng,WANG Yi-bin,YE Gui-rong,ZHANG Yan-xuan.Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients[J].Journal of Southern Medical University,2007,27(7):1090-1092. |
| |
| Authors: | LIU Xiao-you YU Li-xin FU Shao-jie XU Jian DU Chuan-fu DENG Wen-feng WANG Yi-bin YE Gui-rong ZHANG Yan-xuan |
| |
| Affiliation: | Department of Kidney Transplantation, Nanfang Hospital, Southern Medieal University, Guangzhou 510515, China |
| |
| Abstract: | OBJECTIVE: To compare the long-term effect and safety of tacrolimus (FK506) and cyclosporine (CsA) in kidney transplant (KT) recipients carrying hepatitis B Virus(HBV). METHODS: A total of 109 patients with HBV were randomized into FK506 group (52 cases) and CsA group (57 cases) after KT, and a 2-year-long follow-up of the patients was conducted to record the patient and graft survival, incidence of acute graft rejection and postoperative liver function. RESULTS: The 2-year patient/graft survival was 86.0%/73.7% and 94.2%/90.3% in CsA and FK506 groups, respectively (P<0.05), with incidence of acute rejection of 10.5% and 9.6% (P>0.05), and rate of abnormal liver function of 26.3% and 15.4% (P<0.05), respectively. Eight patients (14.4%) in CsA group required a drug conversion but none in FK506 group. The drug conversion resulted in significant reduction of ALT/AST level from 255.13+/-31.38/201.88+/-21.25 U/L to 31.25+/-11.50/25.13+/-9.68 U/L (P<0.01). CONCLUSION: For HBV-carrying renal transplant recipients, FK506 as the primary choice of immunosuppressant can be more effective and safer than CsA. |
| |
| Keywords: | hepatitis B Virus carrier kidney transplant tacrolimus cyclosporine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《南方医科大学学报》浏览原始摘要信息 |
|
点击此处可从《南方医科大学学报》下载全文 |
|
